

Special Issue

Oesophageal Adenocarcinoma

Message from the Guest Editor

This Special Issue is about Oesophageal adenocarcinoma (OEA). OEA is among the most lethal conditions gastroenterologists face today, with only 16% of patients surviving 5 years and a median survival time of less than 1 year. Unfortunately, little progress has been made in improving survival and patients' outcome. Oesophageal adenocarcinoma usually presents at a late stage, with most patients presenting with T3 or T4 disease and, thus, high mortality rates. Very few treatment regimens are available. What is more, the incidence of OEA has increased in the last 40 years, by approximately 600% from the 1970s. The reasons for this increase and tumor biology in particular are poorly understood. Treatment of OEA has evolved in recent years, with several new treatment techniques that lead to improvements in oncology, gastroenterology, and surgery. However, recent studies have shown that we are still far away from a clear understanding of oesophageal adenocarcinoma. Here, we welcome papers outlining tumor biology, diagnostics, and treatment modalities of Oesophageal adenocarcinoma.

Guest Editor

Dr. Matthias Reeh

Department of General, Visceral and Thoracic Surgery, University Medical Center, Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany

Deadline for manuscript submissions

closed (18 October 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/58675

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)